PolyPid
Latest round
- Series D
Last raised
- Feb 2016
Total raised
- $22M
Investors
- 2
About PolyPid
a. PolyPid operates as a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies to enhance surgical outcomes. In January 2024, PolyPid Ltd. PolyPid's product candidates are designed for extended, localized release of medications over days to months, targeting issues such as infection, pain, inflammation, and cancer. The company’s flagship products, D-PLEX100 and D-PLEX1000, are specifically developed to prevent surgical site infections and address bone-related infections using advanced, localized delivery mechanisms.
Who invested in PolyPid
2 investors across 1 round
See all investors in PolyPid
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series D
Feb 24, 2016
Amount
$22M
Investors
Questions about PolyPid
Who invested in PolyPid?
PolyPid has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has PolyPid raised?
PolyPid has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did PolyPid last raise money?
PolyPid's most recent round on record is a Series D, in Feb 2016.
What does PolyPid do?
PolyPid is a biotechnology company.
Where is PolyPid headquartered?
PolyPid is headquartered in Petah Tikva, Israel.
Which VCs invest in companies like PolyPid?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at PolyPid's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like PolyPid? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.